anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
atai Life Sciences · pitchdeck

ATAI | Investor Presentation Deck | 34 slides

34 pages · 4 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

ATAI | Investor Presentation Deck | 34 slides

atai Life Sciences · 2024-01
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON
Narrative range 23 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 2 slides 100% 2/2 slides 100% 2/2 slides · 7 hits
— 0/2 slides
50% 1/2 slides 50% 1/2 slides 100% 2/2 slides · 3 hits 100% 2/2 slides · 4 hits Solution 12 slides 100% 12/12 slides 100% 12/12 slides · 60 hits
— 0/12 slides
33.3% 4/12 slides 33.3% 4/12 slides 100% 12/12 slides · 20 hits 100% 12/12 slides · 24 hits Traction 7 slides 100% 7/7 slides 100% 7/7 slides · 41 hits
— 0/7 slides
28.6% 2/7 slides 28.6% 2/7 slides 100% 7/7 slides · 14 hits 100% 7/7 slides · 14 hits Roadmap 2 slides 100% 2/2 slides 100% 2/2 slides · 8 hits
— 0/2 slides
— 0/2 slides
100% 2/2 slides 100% 2/2 slides · 4 hits 100% 2/2 slides · 4 hits

Slide inventory

34
every slide · same image gating as the playbook
01
Slide 1
Includes company logo, mission statement, and date.front_matter
Open slide detail
02
Page number 02 in top right corner.other
Open slide detail
03
Slide 03 of the deck.summarize
Open slide detailBeat · ProblemLoop · Cost Of Inaction
04
The slide uses a Gantt-style visualization to show drug development progress across Preclinical, Phase 1, Phase 2, and Phase 3 stages.plan_implementation
Open slide detailBeat · ProblemLoop · Cost Of Inaction
05
The slide uses a table-like structure to track progress (checkmarks for completed, squares for upcoming) across 8 distinct drug programs.plan_implementation
Open slide detailBeat · SolutionLoop · Cost Of Inaction
06
The slide uses a blue-tinted portrait to evoke a clinical or therapeutic context.transition
Open slide detailBeat · SolutionLoop · Cost Of Inaction
07
Includes two line charts showing PK and PD profiles across different dosage levels.show_traction
Open slide detailBeat · SolutionLoop · Cost Of Inaction
08
The slide outlines a 12-week open-label study with a specific focus on treatment-resistant depression (TRD).plan_implementation
Open slide detailBeat · SolutionLoop · Cost Of Inaction
09
The slide uses a timeline-based process diagram to illustrate the clinical trial flow.plan_implementation
Open slide detailBeat · SolutionLoop · Cost Of Inaction
10
The slide features a stylized portrait of a person, likely a patient or representative, within a circular frame.transition
Open slide detailBeat · SolutionLoop · Cost Of Inaction
11
Includes a map of global disease burden and key product features.present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
12
The slide cites a third-party study (Palhano-Fontes et al.) as proxy evidence for DMT efficacy.show_traction
Open slide detailBeat · SolutionLoop · Cost Of Inaction
13
The slide uses a process flow diagram to show the progression of the trial parts.show_traction
Open slide detailBeat · SolutionLoop · Cost Of Inaction
14
The slide uses a minimalist design with a focus on the product name and target indications, accompanied by a human-centric image.present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
15
The slide uses a line chart to show the change in MADRS scores over 12 weeks for three different dosages.show_traction
Open slide detailBeat · SolutionLoop · Cost Of Inaction
16
The slide outlines two distinct study designs (COMP 005 and COMP 006) with specific primary endpoints at week 6.plan_implementation
Open slide detailBeat · SolutionLoop · Cost Of Inaction
17
The slide uses a minimalist design with a portrait image to signal a shift in topic to a specific therapeutic asset.transition
Open slide detailLoop · Cost Of Inaction
18
The chart illustrates the pharmacokinetic advantage of IV delivery over oral administration.present_solution
Open slide detailLoop · Cost Of Inaction
19
Includes trial objectives and timeline markers for both parts.plan_implementation
Open slide detailLoop · Cost Of Inaction
20
transition
Open slide detailLoop · Cost Of Inaction
21
Includes a map of the world as a visual anchor for global disease burden.present_solution
Open slide detailLoop · Cost Of Inaction
22
The slide uses a line chart to show longitudinal changes in HCQ-29 subscales across three time points (Pre-dose, Discharge, 1 Month).show_traction
Open slide detailLoop · Cost Of Inaction
23
The slide outlines a clinical trial cohort structure and key safety/efficacy outcomes.show_traction
Open slide detailLoop · Cost Of Inaction
24
The slide uses a feature-comparison matrix to highlight the unique value proposition of DMX-1002.compare_peers
Open slide detailLoop · Cost Of Inaction
25
transition
Open slide detailLoop · Cost Of Inaction
26
present_solution
Open slide detailLoop · Cost Of Inaction
27
The slide demonstrates an inverted U-shaped dose response curve.show_traction
Open slide detailLoop · Cost Of Inaction
28
The slide uses a grouped bar chart to visualize T-scores across three cognitive tests (HVLT, Symbol Coding, Category Fluency) for four dosage cohorts.show_traction
Open slide detailLoop · Cost Of Inaction
29
The slide uses a standard clinical trial flow diagram showing randomization into three arms (40mg, 20mg, placebo) over a 6-week period.plan_implementation
Open slide detailLoop · Cost Of Inaction
30
transition
Open slide detailLoop · Cost Of Inaction
31
Includes a map of global disease burden and key product features.present_solution
Open slide detailLoop · Cost Of Inaction
32
Slide 32 of the deck.show_traction
Open slide detailLoop · Cost Of Inaction
33
The slide uses EEG power spectral density analysis to demonstrate target engagement and potential for a superior safety profile (less sedation) compared to stanshow_traction
Open slide detailLoop · Cost Of Inaction
34
Includes company logo and Nasdaq ticker symbol.front_matter
Open slide detailLoop · Cost Of Inaction